Ulcerative colitis: treatment with biologicals

Fabio Vieira Teixeira; Sender Jankiel Miszputen; Eduardo Garcia Vilela; Aderson Omar Mourão Cintra Damião; Andrea Vieira; Idblan Carvalho de Albuquerque; José Miguel Luz Parente; Júlio Maria Fonseca Chebli; Orlando Ambrogini Junior; Rogerio Saad Hossne

Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/77188

Full metadata record

DC Field	Value	Language
dc.creator	Fabio Vieira Teixeira	pt_BR
dc.creator	Sender Jankiel Miszputen	pt_BR
dc.creator	Eduardo Garcia Vilela	pt_BR
dc.creator	Aderson Omar Mourão Cintra Damião	pt_BR
dc.creator	Andrea Vieira	pt_BR
dc.creator	Idblan Carvalho de Albuquerque	pt_BR
dc.creator	José Miguel Luz Parente	pt_BR
dc.creator	Júlio Maria Fonseca Chebli	pt_BR
dc.creator	Orlando Ambrogini Junior	pt_BR
dc.creator	Rogerio Saad Hossne	pt_BR
dc.date.accessioned	2024-10-03T20:09:15Z	-
dc.date.available	2024-10-03T20:09:15Z	-
dc.date.issued	2019	-
dc.citation.volume	65	pt_BR
dc.citation.issue	4	pt_BR
dc.citation.spage	547	pt_BR
dc.citation.epage	553	pt_BR
dc.identifier.doi	https://doi.org/10.1590/1806-9282.65.4.547	pt_BR
dc.identifier.issn	18069282	pt_BR
dc.identifier.uri	http://hdl.handle.net/1843/77188	-
dc.description.abstract	O tratamento farmacológico da retocolite ulcerativa (RU) visa reduzir o processo inflamatório e manter a remissão dos sintomas1,2. Apesar do progresso terapêutico, as opções de tratamento para RU ativa moderada a grave permanecem limitadas, devido ao controle parcial obtido com terapia convencional (sulfasalazina, aminossalicilatos, glicocorticoides e imunossupressores) em uma proporção substancial de pacientes, e a existência de eventos adversos. Atualmente, os medicamentos de escolha para a abordagem terapêutica desses pacientes são os agentes anti-fator de necrose tumoral alfa (anti-TNF-α), infliximabe, adalimumabe e golimumabe, e mais recentemente, o agente anti-integrina (vedolizumabe) antagonista seletivo desta molécula de adesão no intestino	pt_BR
dc.description.resumo	The pharmacological treatment of ulcerative colitis (UC) aims to reduce the inflammatory process and maintain remission of symptoms1,2. Despite the therapeutic progress, treatment options for moderate to severe active UC remain limited, due to the partial control obtained with conventional therapy (sulfasalazine, aminosalicylates, glycyclorticoids and immunosuppressants) in a substantial proportion of patients, and the existence of adverse events. Currently, the drugs of choice for the therapeutic approach of these patients are anti-tumor necrosis factor alpha (anti-TNF-α) agents, infliximab, adalimumab, and golimumab, and more recently, the anti-integrin agent (vedolizumab) selective antagonist of this adhesion molecule in the intestine	pt_BR
dc.format.mimetype	pdf	pt_BR
dc.language	eng	pt_BR
dc.publisher	Universidade Federal de Minas Gerais	pt_BR
dc.publisher.country	Brasil	pt_BR
dc.publisher.department	MED - DEPARTAMENTO DE CLÍNICA MÉDICA	pt_BR
dc.publisher.initials	UFMG	pt_BR
dc.relation.ispartof	Revista da Associação Médica Brasileira	pt_BR
dc.rights	Acesso Aberto	pt_BR
dc.subject	Colitis, Ulcerative	pt_BR
dc.subject	Drug Therapy	pt_BR
dc.subject.other	Colite Ulcerativa	pt_BR
dc.subject.other	Tratamento Farmacológico	pt_BR
dc.title	Ulcerative colitis: treatment with biologicals	pt_BR
dc.title.alternative	Colite ulcerativa: tratamento com biológicos	pt_BR
dc.type	Artigo de Periódico	pt_BR
dc.url.externa	https://www.scielo.br/j/ramb/a/YyrcYf6zSFnwGhN4tDfWvDL/?lang=en	pt_BR
Appears in Collections:	Artigo de Periódico

Files in This Item:

File	Description	Size	Format
Ulcerative colitis.pdfA.pdf		110.96 kB	Adobe PDF	View/Open

Show simple item record